Radek Špíšek

13.1k total citations · 2 hit papers
134 papers, 7.6k citations indexed

About

Radek Špíšek is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Radek Špíšek has authored 134 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Immunology, 63 papers in Oncology and 26 papers in Molecular Biology. Recurrent topics in Radek Špíšek's work include Immunotherapy and Immune Responses (72 papers), Immune Cell Function and Interaction (50 papers) and Cancer Immunotherapy and Biomarkers (44 papers). Radek Špíšek is often cited by papers focused on Immunotherapy and Immune Responses (72 papers), Immune Cell Function and Interaction (50 papers) and Cancer Immunotherapy and Biomarkers (44 papers). Radek Špíšek collaborates with scholars based in Czechia, France and United States. Radek Špíšek's co-authors include Jitka Fučíková, Lorenzo Galluzzi, Guido Kroemer, Jiřina Bartůňková, Oliver Kepp, Madhav V. Dhodapkar, Laurence Zitvogel, Anna Fialová, Lenka Kašíková and Daniela Rožková and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Radek Špíšek

130 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Detection of immunogenic cell death and its relevance for cancer therapy

2020 756 citations Jitka Fučíková, Oliver Kepp et al. Cell Death and Disease profile →
Calreticulin and cancer

2020 299 citations Jitka Fučíková, Radek Špíšek et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Radek Špíšek Czechia	45	4.8k	3.3k	1.9k	829	764	134	7.6k
Evelien Smits Belgium	46	3.5k 0.7×	2.8k 0.9×	2.0k 1.1×	615 0.7×	649 0.8×	179	6.8k
Grégoire Mignot France	26	4.5k 0.9×	3.2k 1.0×	2.3k 1.2×	835 1.0×	525 0.7×	49	7.5k
Antoine Tesnière France	20	4.7k 1.0×	3.2k 1.0×	2.1k 1.1×	1.1k 1.4×	651 0.9×	27	7.6k
Jitka Fučíková Czechia	37	3.6k 0.7×	2.8k 0.8×	1.5k 0.8×	767 0.9×	637 0.8×	70	5.6k
Veena Kapoor United States	44	6.1k 1.3×	5.2k 1.6×	2.5k 1.3×	1.0k 1.2×	777 1.0×	96	10.4k
Chrystal M. Paulos United States	39	5.5k 1.1×	5.4k 1.6×	2.3k 1.2×	795 1.0×	373 0.5×	132	9.2k
Sandra Hervás‐Stubbs Spain	39	3.7k 0.8×	2.8k 0.9×	2.1k 1.1×	419 0.5×	521 0.7×	111	6.7k
Pedro Berraondo Spain	36	3.3k 0.7×	2.9k 0.9×	1.8k 1.0×	463 0.6×	451 0.6×	164	5.9k
Kristen E. Pauken United States	27	5.4k 1.1×	4.5k 1.4×	1.4k 0.7×	292 0.4×	622 0.8×	39	8.0k
Ferdy J. Lejeune Switzerland	44	3.2k 0.7×	3.3k 1.0×	2.6k 1.4×	435 0.5×	1.0k 1.3×	119	7.3k

Countries citing papers authored by Radek Špíšek

Since Specialization

Citations

This map shows the geographic impact of Radek Špíšek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Radek Špíšek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Radek Špíšek more than expected).

Fields of papers citing papers by Radek Špíšek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Radek Špíšek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Radek Špíšek. The network helps show where Radek Špíšek may publish in the future.

Co-authorship network of co-authors of Radek Špíšek

This figure shows the co-authorship network connecting the top 25 collaborators of Radek Špíšek. A scholar is included among the top collaborators of Radek Špíšek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Radek Špíšek. Radek Špíšek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Truxová, Iva, Jana Raková, Cyril Šálek, et al.. (2023). Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients. Cell Death and Disease. 14(3). 209–209. 15 indexed citations

Guilbaud, Emma, Vanessa Klapp, Iva Truxová, et al.. (2023). Type I interferon and cancer. Immunological Reviews. 321(1). 115–127. 55 indexed citations

Truxová, Iva, David Cibula, Radek Špíšek, & Jitka Fučíková. (2023). Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma. Journal for ImmunoTherapy of Cancer. 11(2). e005968–e005968. 43 indexed citations

Rob, Lukáš, David Cibula, Paweł Knapp, et al.. (2022). Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. Journal for ImmunoTherapy of Cancer. 10(1). e003190–e003190. 31 indexed citations

Fučíková, Jitka, An Coosemans, Sandra Oršulić, et al.. (2021). Immunological configuration of ovarian carcinoma: features and impact on disease outcome. Journal for ImmunoTherapy of Cancer. 9(10). e002873–e002873. 33 indexed citations

Kašíková, Lenka, Iva Truxová, Isabelle Cremer, et al.. (2019). Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death. Methods in enzymology on CD-ROM/Methods in enzymology. 632. 15–25. 3 indexed citations

D’Amico, Lucia, Ulrike Menzel, Michael Prummer, et al.. (2019). A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. Journal for ImmunoTherapy of Cancer. 7(1). 16–16. 89 indexed citations

Funda, David P., et al.. (2019). Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?. Frontiers in Immunology. 10. 967–967. 13 indexed citations

Bezu, Lucillia, Oliver Kepp, Giulia Cerrato, et al.. (2018). Trial watch: Peptide-based vaccines in anticancer therapy. OncoImmunology. 7(12). e1511506–e1511506. 120 indexed citations

10.

Truxová, Iva, Lenka Kašíková, Michal Hensler, et al.. (2018). Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. Journal for ImmunoTherapy of Cancer. 6(1). 139–139. 144 indexed citations

11.

Sadílková, Lenka, et al.. (2017). Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy. PLoS ONE. 12(2). e0171539–e0171539. 25 indexed citations

12.

Adkins, Irena, et al.. (2016). Case-Control Study: Smoking History Affects the Production of Tumor Antigen–Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease–Free Group. Journal of Thoracic Oncology. 12(2). 249–257. 10 indexed citations

13.

Bloy, Norma, Aitziber Buqué, Fernando Aranda, et al.. (2015). Trial watch: Naked and vectored DNA-based anticancer vaccines. OncoImmunology. 4(5). e1026531–e1026531. 32 indexed citations

14.

Vacchelli, Erika, Fernando Aranda, Norma Bloy, et al.. (2015). Trial Watch—Immunostimulation with cytokines in cancer therapy. OncoImmunology. 5(2). e1115942–e1115942. 44 indexed citations

15.

Kocián, Petr, Monika Šedivcová, Jeffrey S. Hoch, et al.. (2012). [K-ras mutational status and tumour-infiltrating lymphocytes in human colon cancer: state of the art and future perspectives].. PubMed. 91(8). 427–32. 2 indexed citations

16.

Pajer, Petr, et al.. (2009). Dendritic Cell-Based Immunotherapy Induces Transient Clinical Response in Advanced Rat Fibrosarcoma – Comparison with Preventive Anti-tumour Vaccination. Folia Biologica. 55(4). 119–125. 2 indexed citations

17.

Lašťovička, Jan, et al.. (2009). Assessment of lymphocyte proliferation: CFSE kills dividing cells and modulates expression of activation markers. Cellular Immunology. 256(1-2). 79–85. 70 indexed citations

18.

Sochorová, Klára, Rudolf Horváth, Daniela Rožková, et al.. (2006). Impaired Toll-like receptor 8–mediated IL-6 and TNF-α production in antigen-presenting cells from patients with X-linked agammaglobulinemia. Blood. 109(6). 2553–2556. 70 indexed citations

19.

Špíšek, Radek, Gwenola Bougras, Frédéric Ebstein, et al.. (2003). Transient exposure of dendritic cells to maturation stimuli is sufficient to induce complete phenotypic maturation while preserving their capacity to respond to subsequent restimulation. Cancer Immunology Immunotherapy. 52(7). 445–454. 27 indexed citations

20.

Špíšek, Radek & Patrice Chevallier. (2002). Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.. PubMed. 62(10). 2861–127. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact